Therefore, targeting GABPB1 for anti-telomerase cancer therapy may counteract its tumor-suppressive activity, thereby promoting TC progression, which should be considered in the rational development of telomerase-based strategies against cancer. Here, GABPB1 is linked to neoplasm.